Covid-19 roundup: Shionogi’s antiviral pill hits the mark; Ocugen strikes deal for intranasal vaccine
Japanese pharma Shionogi’s Covid-19 antiviral against Omicron passed its Phase III trial in Asia, meeting its primary endpoint.
The drug, a protease inhibitor known as ensitrelvir, was administered daily for five days and led to a significant reduction in symptoms such as stuffy or runny nose, sore throat, cough, feeling hot or feverish, and low energy or tiredness within 72 hours of its onset, the company announced Wednesday. A total of 1,821 mostly vaccinated patients from Japan, South Korea and Vietnam were enrolled in the study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.